These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33025237)

  • 21. Crush resistance and insufflation potential of poly(ethylene oxide)-based abuse deterrent formulations.
    Muppalaneni S; Mastropietro DJ; Omidian H
    Expert Opin Drug Deliv; 2016 Oct; 13(10):1375-82. PubMed ID: 27402156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations.
    Wening K; Schwier S; Stahlberg HJ; Galia E
    J Opioid Manag; 2017; 13(6):473-484. PubMed ID: 29308593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets.
    Li H; Hardy RJ; Gu X
    AAPS PharmSciTech; 2008; 9(2):437-43. PubMed ID: 18431663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the impact of abuse deterring agents on the physicochemical factors of tramadol-loaded tablet and the definition of new abuse deterrent index.
    Won DG; Park G; Ngo HV; Jin G; Park C; Lee BJ
    Int J Pharm; 2021 Aug; 605():120726. PubMed ID: 34029664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abuse-deterrent properties and cytotoxicity of poly(ethylene oxide) after thermal tampering.
    Babanejad N; Kandalam U; Ahmad R; Omidi Y; Omidian H
    Int J Pharm; 2021 May; 600():120481. PubMed ID: 33766634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of drug release from aged prolonged polyethylene oxide tablet matrices: effect of excipient and drug type.
    Shojaee S; Kaialy W; Cumming KI; Nokhodchi A
    Pharm Dev Technol; 2016 Mar; 21(2):189-95. PubMed ID: 25410967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion.
    Xu X; Siddiqui A; Srinivasan C; Mohammad A; Rahman Z; Korang-Yeboah M; Feng X; Khan M; Ashraf M
    AAPS PharmSciTech; 2019 Jun; 20(6):230. PubMed ID: 31227939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetrical Flow Field Flow Fractionation for Molar Mass Characterization of Polyethylene Oxide in Abuse-Deterrent Formulations.
    Qu H; Smith WC; Feng X; Wang J; Pinto J; Xu X; Faustino PJ
    J Chromatogr A; 2023 Aug; 1705():464186. PubMed ID: 37453175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended release pellets prepared by hot melt extrusion technique for abuse deterrent potential: Category-1 in-vitro evaluation.
    Butreddy A; Sarabu S; Dumpa N; Bandari S; Repka MA
    Int J Pharm; 2020 Sep; 587():119624. PubMed ID: 32653597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical barrier type abuse-deterrent formulations: monitoring sintering-induced microstructural changes in polyethylene oxide placebo tablets by near infrared spectroscopy (NIRS).
    Boyce HJ; Ibrahim A; Hoag SW
    Drug Dev Ind Pharm; 2018 Nov; 44(11):1885-1894. PubMed ID: 30070152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation and in vitro evaluation of sustained release matrix tablets using cross-linked natural gum.
    Jamil QA; Masood MI; Jamil MN; Masood I; Iqbal SM
    Pak J Pharm Sci; 2017 Mar; 30(2):355-362. PubMed ID: 28649056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk based in vitro performance assessment of extended release abuse deterrent formulations.
    Xu X; Gupta A; Al-Ghabeish M; Calderon SN; Khan MA
    Int J Pharm; 2016 Mar; 500(1-2):255-67. PubMed ID: 26784976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A better dissolution method for ranitidine tablets USP.
    Cappola ML
    Pharm Dev Technol; 2001; 6(1):11-7. PubMed ID: 11247270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Intestine Model Apparatus for Drug Dissolution Capable of Simulating the Peristaltic Action.
    Hribar M; Trontelj J; Klančar U; Markun B; Čeligoj Dujc T; Legen I
    AAPS PharmSciTech; 2017 Jul; 18(5):1646-1656. PubMed ID: 27663704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injection moulded controlled release amorphous solid dispersions: Synchronized drug and polymer release for robust performance.
    Deshmukh S; Paradkar A; Abrahmsén-Alami S; Govender R; Viridén A; Winge F; Matic H; Booth J; Kelly A
    Int J Pharm; 2020 Feb; 575():118908. PubMed ID: 31809859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing.
    Externbrink A; Sharan S; Sun D; Jiang W; Keire D; Xu X
    Int J Pharm; 2019 Apr; 561():305-313. PubMed ID: 30862508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the potential use of poly(ethylene oxide) as tablet- and extrudate-forming material.
    Pinto JF; Wunder KF; Okoloekwe A
    AAPS PharmSci; 2004 Apr; 6(2):e15. PubMed ID: 15760045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the performance of wet granulation and tablet hardness affect the drug dissolution profile of carvedilol in matrix tablets?
    Košir D; Ojsteršek T; Vrečer F
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1543-1550. PubMed ID: 29848075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of manufacturing process variables on in vitro dissolution characteristics of extended-release tablets formulated with hydroxypropyl methylcellulose.
    Huang Y; Khanvilkar KH; Moore AD; Hilliard-Lott M
    Drug Dev Ind Pharm; 2003 Jan; 29(1):79-88. PubMed ID: 12602495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid extended-release tablets with improved tamper-resistant properties.
    Bartholomaeus JH; Arkenau-Marić E; Galia E
    Expert Opin Drug Deliv; 2012 Aug; 9(8):879-91. PubMed ID: 22690792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.